Displaying drugs 16076 - 16100 of 16204 in total
3-Nitrophenylboronic Acid
Experimental
Para-Bromobenzyl Alcohol
Experimental
4-Fluorobenzylamine
Experimental
3-Iodo-Benzyl Alcohol
Experimental
3,3',5,5'-tetrachlorobiphenyl-4,4'-diol
Experimental
2-Iodobenzylthio Group
Experimental
AL6528
Experimental
5-(2-CHLORO-4-NITROPHENYL)-2-FUROIC ACID
Experimental
(4-ETHYLPHENYL)SULFAMIC ACID
Experimental
5-(3-(2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy)propyl)-3-methyl isoxazole
5-(3-(2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy)propyl)-3-methyl isoxazole is a solid. This compound belongs to the phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring. Known drug targets of 5-(3-(2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy)propyl)-3-methyl isoxazole include genome polyprotein.
Experimental
Sulbentine
Experimental
Guanoclor
Experimental
EHT899
EHT899 is a proprietary formulation of an HBV viral protein designed to eliminate the undesirable immune response elicited by the HBV infection. It also apparently enhances a secondary immune response to clear the viral infection, resulting in reduction in liver damage and decrease in viral load.
Investigational
Matched Description: … enhances a secondary immune response to clear the viral infection, resulting in reduction in liver damage and …
RUS 3108
RUS 3108 is being developed for the treatment of atherosclerosis, the major cause of cardiovascular disorders such as heart attacks and stroke by Dr. Reddy’s Laboratories.
The drug’s Phase I clinical trials have been initiated in Europe to assess safety of the drug compound in healthy volunteers.
Investigational
Matched Description: … the treatment of atherosclerosis, the major cause of cardiovascular disorders such as heart attacks and …
Displaying drugs 16076 - 16100 of 16204 in total